Cardiovascular pharmacogenomics: current status and future directions-report of a national heart, lung, and blood institute working group.

"Disclosures All Working Group participants are listed as authors on this manuscript. Dr Roden reports serving as a consultant for Astellas and Warner Chilcott within the last year, as well as receiving royalty payments on a patent on a DNA variant to predict drug-induced arrhythmia; he is also supported by NIH grants U19HL065962 for the Vanderbilt site of the Pharmacogenomics Research Network and U01HG006378 for the Vanderbilt site of the Electronic Medical Records and Genomics Network. Dr Bristow is an employee of and shareholder in ARCA biopharma, Inc, a company developing genetically targeted therapies for cardiovascular diseases. Dr McCaffrey holds equity in Cellgenex, Inc, a privately held company developing genomically guided diagnostic tests in the cardiovascular sector. Dr Wohlgemuth is an employee of and shareholder in Quest Diagnostics, Inc, which markets a number of pharmacogenomic tests, including tests for VKORC1, CYP2C9, CYP2C19, and KIF6 variants, and a shareholder in XDx, Inc, which markets AlloMap testing for transplant rejection. Dr Zineh is an employee of the US Food and Drug Administration; this article may not necessarily reflect US Food and Drug Administration policy, and no official endorsement is intended nor should be inferred. The other authors report no relevant disclosures."

"Sources of Funding The Working Group meeting was underwritten by the National Heart, Lung, and Blood Institute at the National Institutes of Health, Bethesda, MD. The New Frontiers in Personalized Medicine: Cardiovascular Research and Clinical Care was supported and/or cosponsored by the National Heart, Lung, and Blood Institute; Personalized Medicine Coalition; American College of Cardiology; American Medical Association; and the Cheney Cardiovascular Institute at George Washington University."